Workflow
Revenue decreased 1.3%
icon
Search documents
中华港股通优选50指数上涨0.68%,前十大权重包含阿里巴巴-W等
Jin Rong Jie· 2025-06-23 14:20
从中华港股通优选50指数持仓样本的行业来看,金融占比39.95%、可选消费占比24.30%、通信服务占 比16.07%、信息技术占比8.78%、能源占比3.88%、房地产占比3.27%、公用事业占比1.70%、主要消费 占比0.89%、工业占比0.81%、医药卫生占比0.35%。 本文源自:金融界 作者:行情君 数据统计显示,中华港股通优选50指数近一个月下跌1.18%,近三个月下跌3.74%,年至今上涨 17.56%。 据了解,"中华港股通优选50指数由中华证券交易服务有限公司(中华交易服务)委托中证指数有限公司 (中证指数)进行编制,指数编制方案由中华交易服务以及中证指数共同确定。中华港股通优选50指数(中 华港股通优选50)为证券价格指数,旨在反映"港股通"内证券,于香港联合交易所上市市值首五十名蓝 筹证券之整体表现。"该指数以2011年12月30日为基日,以2000.0点为基点。 从指数持仓来看,中华港股通优选50指数十大权重分别为:汇丰控股(9.97%)、腾讯控股 (9.91%)、阿里巴巴-W(9.62%)、小米集团-W(6.88%)、建设银行(6.48%)、美团-W (5.54%)、友邦保险(5. ...
晨化股份: 第五届董事会第一次会议决议公告
Zheng Quan Zhi Xing· 2025-06-23 14:19
证券代码:300610 证券简称:晨化股份 公告编号:2025-060 扬州晨化新材料股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 扬州晨化新材料股份有限公司(以下简称"公司")于 2025 年 6 月 23 日 召开 2025 年第一次临时股东会,选举产生第五届董事会。为保证新一届董事会 工作的正常运行,经全体董事同意豁免会议通知时间要求,公司于同日下午在 江苏省宝应县淮江大道 999 号公司十一楼 1102 会议室召开第五届董事会第一次 会议。 本次会议应到董事 9 人,实到董事 9 人;公司高级管理人员列席了会议。 经全体董事推选,会议由董事于子洲先生主持。本次会议的召开符合《中华人 民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事投票表决,审议通过了如下决议: (一)审议通过了《关于选举公司第五届董事会董事长的议案》 经全体董事审议,同意选举于子洲先生为公司第五届董事会董事长,任期 三年,自本次董事会审议通过之日起至第五届董事会任期届满之日止。 审议结果:9 票同意,0 票反对,0 ...
淳中科技: 北京淳中科技股份有限公司2024年年度权益分派实施公告
Zheng Quan Zhi Xing· 2025-06-23 14:19
证券代码:603516 证券简称:淳中科技 公告编号:2025-031 北京淳中科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ? 每股分配比例 A 股每股现金红利0.25元 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权(息)日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | A股 | 2025/6/27 | - | 2025/6/30 | 2025/6/30 | | 二、 分配方案 ? 差异化分红送转: 是 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 26 日的2024年年度股东会审议通过。 公司根据上海证券交易所的相关规定,将按照以下公式计算除权除息开盘参考价:除权 (息)参考价格=(前收盘价格-现金红利)÷(1+流通股份变动比例) 截至股权登记日下午上海证券交易所收市后,在中国证券登记结算有限责任公司上海分 公司(以下简称"中国结算上海分公司")登记在册的本公司全体股 ...
广州港: 广州港股份有限公司关于第四届董事会第二十六次会议决议的公告
Zheng Quan Zhi Xing· 2025-06-23 14:19
关于第四届董事会第二十六次会议决议的公告 证券代码:601228 证券简称:广州港 公告编号:2025-032 债券代码:185969.SH、137626.SH、137812.SH、115012.SH、240489.SH、243016.SH、243145.SH 债券简称:22 粤港 02、22 粤港 03、22 粤港 04、23 粤港 01、24 粤港 01、25 粤港 01、25 粤港 02 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会召开情况 (一)本次会议的召集、召开符合《中华人民共和国公司法》《公司章程》 及相关法律、法规的要求。 广州港股份有限公司 该议案已经公司第四届董事会战略委员会第四次会议审议通过,并同意提交 本次董事会会议审议。 表决结果:8 票同意,0 票反对,0 票弃权。 (二)会议通知已于 2025 年 6 月 17 日以书面或电子邮件方式送交公司全体 董事。 (三)会议时间:2025 年 6 月 23 日 16:20 会议地点:广州市越秀区沿江东路 406 号港口中心 2706 会议室 ...
C3.ai Ramps Up Partner-Led Sales Model: Can It Drive Scalable Growth?
ZACKS· 2025-06-23 14:15
Core Insights - C3.ai, Inc. is focusing on a go-to-market strategy that leverages its expanding partner ecosystem, achieving 73% of agreements through strategic partners in Q4 of fiscal 2025 [1][9] - The company signed 193 deals through its partner ecosystem in fiscal 2025, marking a 68% increase from the previous year [1][9] - In Q4, C3.ai experienced a 419% increase in partner-supported bookings, closing 59 agreements through strategic alliances [1][2][9] Partner Ecosystem - C3.ai closed 59 partner-led deals in the fiscal fourth quarter, with a significant focus on its alliance with Microsoft, which included 28 joint deals emphasizing manufacturing and chemicals [2][9] - The company is targeting over 600 accounts in collaboration with Microsoft and is also expanding partnerships with AWS, Google Cloud, and consulting firms like PwC and McKinsey QuantumBlack [4][9] Revenue and Investment - To support its channel-centric strategy, C3.ai has invested in demo licenses and enablement tools, which accounted for nearly 30% of its Q4 revenues [3] - The management is optimistic about the potential of consulting partners to enhance scalability and market penetration in future periods [4] Competitive Landscape - Compared to C3.ai, Palantir Technologies Inc. follows a more vertically integrated model, focusing on direct client engagement rather than a partner-led sales approach [5] - Snowflake Inc. is adopting a hybrid model that combines direct go-to-market strategies with strong platform partnerships, enhancing its offerings in the public sector [6][7] Financial Performance - C3.ai's shares have increased by 0.5% over the past three months, slightly outperforming the industry growth of 0.3% [8] - The company trades at a forward price-to-sales ratio of 6.50X, significantly lower than the industry average of 18.47X [11] - The Zacks Consensus Estimate for C3.ai's fiscal 2026 and 2027 earnings per share (EPS) indicates a year-over-year increase of 9.8% and 56.9%, respectively [12]
Best Growth Stocks to Buy for June 23rd
ZACKS· 2025-06-23 14:15
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today June 23rd:Great Lakes Dredge & Dock (GLDD) These company which is the largest provider of dredging services in the US conducting business to maintain and deepen shipping channels, reclaim land from the ocean, and renourish storm damaged coastline, carries a Zacks Rank #1 (Strong Buy), and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 39.1% over the last 60 days.Great L ...
UGI's AmeriGas Propane to Divest Hawaii Assets by Fiscal Q4 2025
ZACKS· 2025-06-23 14:15
Key Takeaways UGI's AmeriGas is selling Hawaii propane assets to Isle Gas, with closing expected in Q4 fiscal 2025. The deal includes 750,000 gallons of storage and a delivery fleet, with proceeds used to reduce debt. UGI aims to boost efficiency and fund growth by exiting non-core markets and cutting long-term costs.UGI Corporation (UGI) announced that its subsidiary, AmeriGas Propane, L.P. (AmeriGas), has entered into a definitive agreement to divest some of its assets in Hawaii to Isle Gas, a wholly ow ...
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
ZACKS· 2025-06-23 14:15
Key Takeaways JNJ's Darzalex gets CHMP nod to treat high-risk smoldering multiple myeloma in adults. Imbruvica also earns CHMP support for frontline mantle cell lymphoma use with chemo. Both decisions are backed by phase III studies showing significant survival improvements.J&J (JNJ) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting label expansion to its two key products, Darzalex and Imbruvica, across separate new indications.CHMP Endorses JNJ’s Darzal ...
Accenture (ACN) Reliance on International Sales: What Investors Need to Know
ZACKS· 2025-06-23 14:15
Have you evaluated the performance of Accenture's (ACN) international operations for the quarter ending May 2025? Given the extensive global presence of this consulting company, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For inves ...
Insights Into Lindsay (LNN) Q3: Wall Street Projections for Key Metrics
ZACKS· 2025-06-23 14:15
In its upcoming report, Lindsay (LNN) is predicted by Wall Street analysts to post quarterly earnings of $1.36 per share, reflecting a decline of 3.6% compared to the same period last year. Revenues are forecasted to be $162.01 million, representing a year-over-year increase of 16.4%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company reve ...